HK2 and ovarian carcinoma: HK2 acts as a mediator to facilitate glucose metabolic reprogramming, thereby enhancing the malignant potential and promoting cell autophagy through FAK/MAPK kinase signaling to confer resistance against cisplatin therapy in ovarian cancer stem cells 13.